Detection of PDGFRA mutations at exons 12 and 18 among chronic myeloid leukemia patients treated with imatinib mesylate
Imatinib mesylate (IM) resistance is an emerging and major challenge in the treatment of patients with chronic myeloid leukaemia (CML). Resistance toward IM can be divided into BCR-ABL dependent pathways and BCR-ABL independent pathway. In this study, the BCRABL independent pathway was investigated;...
Main Author: | Razali, Ruzi Hamimi |
---|---|
Format: | Thesis |
Language: | English |
Published: |
2015
|
Subjects: | |
Online Access: | http://eprints.usm.my/39897/1/Dr_Ruzi_Hamimi_Razali_%28Medical_Genetics%29-24_pages.pdf |
Similar Items
-
Imatinab mesylate treatment in Chronic Myeloid
Leukemia (CML)- understanding the
fundamental pharmacokinetic and
pharmacogenetic mechanisms for variation in
response
by: Ankathil, Ravindran
Published: (2016) -
Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience
by: Bee, P.C., et al.
Published: (2006) -
Ultra-high performance liquid chromatography
(uhplc) method development and validation for the
determination of serum imatinib and its active
metabolite concentration among chronic myeloid
leukemia patients
by: Liong, Tan Ka
Published: (2013) -
Translation termination mutations analysis using the protein truncation test on exon11A of the BRCA1 gene in female breast cancer patients of Pahang, Malaysia
by: Alattraqchi, Ahmed G., et al.
Published: (2012) -
TP53 mutations are infrequent in newly diagnosed chronic lymphocytic leukimia
by: Zainuddin, Norafiza, et al.
Published: (2011)